Trials / Completed
CompletedNCT04111484
Adrenomedullin Effect on Migraine Without Patients
Adrenomedullins Headache Inducing Effects on Migraine Without Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Danish Headache Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
AM is a naturally occurring peptide in the body and consists of 52 amino acids. AM belongs to the calcitonin gene-related peptide (CGRP) superfamily and has several structural, physiological and pharmacological similarities to CGRP, intermdine and amylin. In a randomized double-blind, placebo controlled cross-over design 20 migraine patients without aura recruited to receive infusion of adrenomedullin or placebo (saline).
Detailed description
AM is a naturally occurring peptide in the body and consists of 52 amino acids. AM belongs to the calcitonin gene-related peptide (CGRP) superfamily and has several structural, physiological and pharmacological similarities to CGRP, intermdine and amylin. In a randomized double-blind, placebo controlled cross-over design 20 migraine patients without aura recruited to receive infusion of adrenomedullin or placebo (saline). A pilot study on healthy volunteers were conducted to determine tolerable dose of adrenomedullin to the main study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Adrenomedullin | Adrenomedullin is a naturally found in the human body and has strong vasoactive properties. |
| OTHER | Saline | Placebo |
Timeline
- Start date
- 2019-09-28
- Primary completion
- 2020-01-30
- Completion
- 2020-01-30
- First posted
- 2019-10-01
- Last updated
- 2020-03-02
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04111484. Inclusion in this directory is not an endorsement.